Slide 1: Second quarter
Second quarter CEO Christer Wahlquist CFO Per-Ola Holmström July 18, 2024 1
Slide 2: Q2 summary – Nolato Group
Q2 summary – Nolato Group A global solutions provider established on three continents ● Sales totaled SEK 2,439 million (2,478) - A decrease of 2% adjusted for currency and acquisitions SEKm - VHP effects phased out from Q3 2024 12000 ● Operating profit (EBITA) rose by 24% to SEK 245 11000 million (
Slide 3: One Group – two business areas
One Group – two business areas Nolato Medical Solutions Engineered Solutions Our offering as a strategic partner for selected Development and manufacture of complex Design, development, industrialization and global customers comprises development and product systems and components for medical manufa
Slide 4: Medical Solutions – sustainable growth and global expansion
Medical Solutions – sustainable growth and global expansion SEKm 5500 5000 4500 4000 3500 3000 1,365 149 2500 2000 SALES EBITA-RESULT SEKm, Q2 SEKm, Q2 1500 56 10.9 1000 500 SHARE OF THE GROUP EBITA-MARGIN 0 %, Q2 %, Q2 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 R12M 4 4
Slide 5: Medical Solutions – focused product areas
Medical Solutions – focused product areas Pharma Diagnostics Medical Devices Drug Delivery In-vitro-diagnostics (IVD) Endoscopy & General Surgery Cardiology Continence care Pharma Packaging Other 5
Slide 6: Medical Solutions – Q2
Medical Solutions – Q2 Q2 Acc. 6 months ● Sales unchanged SEKm 2024 2023 2024 2023 - 1% decrease, adjusted for currency - IVD grew compared with a weak quarter last year - Lower volumes in the Other category (customer product recall) Sales 1,365 1,364 2,720 2,688 - Pharmaceutical packaging experienc
Slide 7: Engineered Solutions – advanced technology and high-productivity manufacturing
Engineered Solutions – advanced technology and high-productivity manufacturing SEKm 8000 7500 7000 6500 6000 5500 5000 4500 4000 1,077 108 3500 3000 2500 SALES EBITA-RESULT SEKm, Q2 SEKm, Q2 2000 1500 44 10.0 1000 500 SHARE OF THE GROUP EBITA-MARGIN 0 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20
Slide 8: Engineered Solutions – focused product areas
Engineered Solutions – focused product areas Materials Consumer electronics Automotive Other Hygiene 8
Slide 9: Engineered Solutions – Q2
Engineered Solutions – Q2 ● 3% decrease in sales Q2 Acc. 6 months - A decrease of 4% adjusted for currency and acquisitions SEKm 2024 2023 2024 2023 - Volumes in Consumer Electronics declined this quarter too (minimal volumes with a previously significant customer in VHP products) - The Automotive a
Slide 10: Key performance indicators Group
Full Q2 Q2 Acc. 6 months year SEKm 2024 2023 2024 2023 R12M 2023 Net sales 2,439 2,478 4,881 4,954 9,473 9,546 Operating profit (EBITA)* 245 198 483 391 793 701 Adjusted operating profit (EBITA), excl. non-recurring items in 2023 245 198 483 391 853 761 Adjusted EBITA margin (%), excl. non-recurring
Slide 11: Current situation
Current situation Medical Solutions Engineered Solutions • Maintained growth strategy – but temporarily sluggish • VHP effects phased out from Q3 2024 market activity • Advanced market positions • Focus on margin – cost adjustments, pricing strategy and • Established position in new product areas ef
Slide 12: www.nolato.com
w w w. n o l a t o . c o m This presentation may contain forward-looking statements. When used in this presentation, words such as “anticipate”, “believe”, “estimate”, “expect”, “plan” and “project” are intended to identify forward-looking statements. Such statements could encompass risks and uncert